Vertex's cystic fibrosis research program has yielded two innovative approaches for the treatment of this disease.

178

Vertex achieved all of its clinical, research and financial objectives in 2005. In particular, we increased our financial strength as we advanced potentially transformational compounds targeting hepatitis C virus (HCV), rheumatoid arthritis and cystic fibrosis. Our performance last year has positioned us to build momentum in 2006.

101